Which country and company developed and produced monogravir capsules (molnupiravir)?

Molnupiravir capsules (Molnupiravir) are antiviral drugs developed and produced by the American company Merck (Merck) in cooperation with the American company Ridgeback Biotherapeutics. The drug was developed in response to the COVID-19 pandemic, a global health crisis caused by the novel coronavirus (SARS-CoV-2).

In the early days of the epidemic, scientists and pharmaceutical companies around the world were actively seeking effective treatments. Against this backdrop, Merck and Ridgeback Biotherapeutics are collaborating to develop an oral drug that can reduce viral replication and spread in patients with early COVID-19 infection.

Monoravir's mechanism of action is to inhibit the growth of the virus by interfering with the virus's RNA replication, thereby alleviating the symptoms of COVID-19 and reducing the severity of the disease. The development of this drug represents an urgent collaboration and innovation among scientists and pharmaceutical companies in the face of a global health crisis.

Monoravir capsules have produced some encouraging results in clinical trials, showing that it can reduce the risk of hospitalization and death inCOVID-19 patients in cases of early exposure to the virus. However, the safety and effectiveness of drugs are still being continuously evaluated in research, especially as virus variants continue to emerge.

In short, monogravir capsules are an antiviral drug jointly developed by Merck of the United States and Ridgeback Biotherapeutics Company. It represents the collaborative efforts and innovative results of the scientific community and the pharmaceutical industry in the global fight against the COVID-19 pandemic. It offers a potential new option for early treatment that is expected to play an important role in the global health crisis.

Monolavir capsules are already on the market in China, but are not yet included in medical insurance. Please consult your local hospital pharmacy for specific prices. The cheaper ones abroad are Indian generic drugs, which cost around three to four hundred yuan, and the ingredients of domestic original drugs and foreign generic drugs are basically the same.